A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
Public ClinicalTrials.gov record NCT05050942. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.
Study identification
- NCT ID
- NCT05050942
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 332 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 22, 2021 (Actual)
- Primary completion
- Nov 2026 (Estimated)
- Completion
- Nov 2028 (Estimated)
- Last update posted
- Jul 28, 2026
2021 – 2028
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Cancer Center (MCCC) - Phoenix | Phoenix | Arizona | 85054 | — |
| UCLA Ahmanson Biological Imaging Center | Santa Monica | California | 90404 | — |
| Rocky Mountain Cancer Centers - Denver - Midtown | Denver | Colorado | 80218 | — |
| Mayo Clinic Hospital - Florida | Jacksonville | Florida | 32224 | — |
| University of Kentucky (UK) - Markey Cancer Center | Lexington | Kentucky | 40536 | — |
| East Jefferson General Hospital | Metairie | Louisiana | 70065 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Texas Oncology - Austin | Austin | Texas | 78705 | — |
| Texas Oncology - Dallas | Dallas | Texas | 75246 | — |
| The University of Texas - MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Texas Oncology - McAllen | McAllen | Texas | 78503 | — |
| Texas Oncology - San Antonio Northeast | San Antonio | Texas | 78240 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 71 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05050942, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 28, 2026 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05050942 live on ClinicalTrials.gov.